Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TPMT | P51580 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | XDH | P47989 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.53 |
| ▸ | GFER | P55789 | 1/20 | 0.53 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.53 |
| ▸ | RELA | Q04206 | 1/20 | 0.53 |
| ▸ | FUT7 | Q11130 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | CNR2 | P34972 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL989006 | 0.90 | VCAM1 (0.56) | TPMTKDM4ELMNAPOLBL3MBTL1 | |
| SCHEMBL31440703 | 0.85 | KDM4E (0.65) | TPMTKDM4EXDHLMNAPOLB | |
| SCHEMBL643856 | 0.85 | KDM4E (0.65) | TPMTKDM4EXDHLMNAPOLB | |
| SCHEMBL31161317 | 0.85 | VCAM1 (0.52) | TPMTKDM4ELMNAPOLBVCAM1 | |
| SCHEMBL15432231 | 0.85 | VCAM1 (0.52) | TPMTKDM4ELMNAPOLBVCAM1 | |
| SCHEMBL5924211 | 0.83 | ESR1 (0.57) | TPMTKDM4EXDHLMNAPOLB | |
| SCHEMBL2671409 | 0.83 | VCAM1 (0.50) | TPMTKDM4ELMNAPOLBGAA | |
| SCHEMBL12774975 | 0.83 | VCAM1 (0.50) | TPMTKDM4ELMNAPOLBGAA | |
| SCHEMBL20839509 | 0.83 | TPMT (0.54) | TPMTKDM4EXDHLMNAPOLB | |
| SCHEMBL2671510 | 0.83 | VCAM1 (0.50) | TPMTKDM4EXDHLMNAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100298324-A1 | Prolyl Hydroxylase Inhibitors | SMITH KLINE BEECHAM CORPORATION (US) | 2010-11-25 | — | — | US | disclosed |
| US-20100298324-A1 | Prolyl Hydroxylase Inhibitors | SMITH KLINE BEECHAM CORPORATION (US) | 2010-11-25 | — | — | US | disclosed |
| US-20100298324-A1 | Prolyl Hydroxylase Inhibitors | SMITH KLINE BEECHAM CORPORATION (US) | 2010-11-25 | — | — | US | disclosed |
| EP-2240178-A1 | PROLYL HYDROXYLASE INHIBITORS | GlaxoSmithKline LLC (US) | 2010-10-20 | — | — | EP | disclosed |
| WO-2010059549-A1 | PROLYL HYDROXYLASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2010-05-27 | — | — | WO | disclosed |
| WO-2010059549-A1 | PROLYL HYDROXYLASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2010-05-27 | — | — | WO | disclosed |
| WO-2009086044-A1 | PROLYL HYDROXYLASE INHIBITORS | SMITH KLINE BEECHAM CORPORATION (US) | 2009-07-09 | — | — | WO | disclosed |
| WO-2009086044-A1 | PROLYL HYDROXYLASE INHIBITORS | SMITH KLINE BEECHAM CORPORATION (US) | 2009-07-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298324-A1 | Prolyl Hydroxylase Inhibitors | HIF1AN, EGLN3, EGLN2 | TPMT 234/4885KDM4E 206/4885XDH 66/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.